EN
Home/Canada/Blog/Does private insurance cover Ozempic, Wegovy or Zepbound in Canada?
CACanada Coverage and insurance

Does private insurance cover Ozempic, Wegovy or Zepbound in Canada?

How workplace drug plans handle GLP‑1 medicines: how many cover weight loss, what the prior authorization form asks, and what changes when a generic exists.

GLP Guidebook teamPublished 12 Oct 20268 min read16 sourcesWritten from published sources

Written for Canada. Reading from India? India version

The short answer

Sometimes. In a 2026 survey, 37% of Canadian employers covered GLP‑1s for weight loss as well as diabetes, up from 17% in 2024; 51% covered them for diabetes only. Plans that cover weight loss usually want a prior authorization form showing your BMI, and a 5% weight loss to renew.

Key takeaways

  • In a 2026 employer survey, 37% of Canadian plans covered GLP‑1s for weight loss and diabetes, up from 17% in 2024.1,2
  • Another 51% of employers covered GLP‑1s for diabetes only, so most plans in the survey covered Ozempic-type medicines for diabetes.1
  • One benefits manager’s Wegovy form asks for a BMI of 30 or more, or 27 or more with a weight-related condition, and a 5% weight loss to renew.3
  • The same form says requests for uses Health Canada hasn’t approved may be denied, which matters for Ozempic or Mounjaro prescribed for weight.3
  • Insurers paid nearly $77 million for weight-management drugs in 2024, double the $38 million paid in 2023, according to Telus Health data.4
Before you go further
  • GLP‑1 medicines are prescription drugs in Canada. Nothing here is a reason to start, stop or switch one.5
  • We name brands and official prices as facts. We don’t recommend, rank or link to any brand, pharmacy, clinic or program.
  • For weight management, Health Canada has approved Wegovy, Zepbound and Saxenda, and the generic Sevmia. Ozempic and Mounjaro are approved for type 2 diabetes.6,5
  • Trial results are averages. Some people lose much less, and every benefit comes with risks: see our side effects guide.
On this page
  1. How many workplace plans cover GLP‑1s for weight loss?
  2. What does a prior authorization form ask for?
  3. Will my plan cover Ozempic if I have type 2 diabetes?
  4. What if Ozempic or Mounjaro is prescribed for weight?
  5. What about Quebec, and personal plans?
  6. Questions people ask
  7. How we researched this
  8. Sources

How many workplace plans cover GLP‑1s for weight loss?

About a third. In the International Foundation of Employee Benefit Plans’ 2026 survey, 37% of Canadian employers covered GLP‑1s for weight loss as well as diabetes.1

That was up from 17% in 2024 and 31% in 2025. A further 51% covered them for diabetes only, and 12% also covered other conditions such as sleep apnea.1,2

Most plans that cover weight loss treat the medicine as an ordinary prescription drug (85%). Others use a separate weight-management vendor (12%) or an add-on rider (4%).1 Among employers that don’t cover weight loss, 15% point staff to a health care spending account.1

Cost is part of the reason. Telus Health data show insurers paid nearly $77 million for weight-management drugs in 2024, up from $38 million in 2023. The average was $2,012 per claimant.4

What does a prior authorization form ask for?

Your BMI and weight, any weight-related conditions, what you have tried before and, at renewal, proof you lost at least 5% of your weight.3

Prior authorization means the plan approves the drug for you before it pays. Your prescriber fills in part of the form. Here is what one benefits manager’s Wegovy form asks:3

  • First request: an adult with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol.3
  • Renewal: a loss of 5% or more of body weight, with your starting and current weight.3
  • History: medicines you tried before, and why they stopped.3
  • Other coverage: whether a provincial plan or another plan has already decided.3

Two lines in the small print matter. “Any fees related to the completion of this form are the responsibility of the plan member.” And: “Drugs used for indications not approved by Health Canada may be denied.”3

Those BMI thresholds match Wegovy’s approved use in Canada.7 The 5% renewal rule is the same one Canada’s Drug Agency set for public funding.8

Free toolWork out a 6- or 12-month cost

Pick a medicine and a dose plan, then add what your plan pays. No sign-up.

Open the calculator

Will my plan cover Ozempic if I have type 2 diabetes?

More often than for weight: at least 88% of employers in the 2026 survey covered GLP‑1s for diabetes. But many plans now pay only the generic price.1,9,10

Generic semaglutide changed the maths in 2026. From 17 August 2026, Alberta Blue Cross applies generic pricing to Ozempic claims under private plans that follow generic pricing.9

Saskatchewan Blue Cross says plans with mandatory generic substitution limit payment to the lowest-priced interchangeable product. If you choose the brand, you may pay the difference.10 Which generics exist: generic semaglutide in Canada.

What if Ozempic or Mounjaro is prescribed for weight?

That is an off-label use in Canada, and a plan can decline it. The form above warns that unapproved uses “may be denied”.3,11,12

Ozempic and Mounjaro are approved for type 2 diabetes. Wegovy and Zepbound, with the same medicines, are the brands approved for weight.11,12,7,13 See Zepbound vs Mounjaro.

What plans pay for: in STEP 1, the main Wegovy trial, people on 2.4 mg lost 14.9% of their body weight on average over 68 weeks, against 2.4% on a dummy injection. For someone starting at 90 kg (198 lb), 14.9% is about 13 kg (29 lb); some lost much more, some very little.7 The harms come with it.

RisksThe risks, in brief
  • Stomach effects. About 44 in 100 people on Wegovy 2.4 mg felt sick (nausea), against 16 in 100 on a dummy injection. On Zepbound 15 mg it was about 28 in 100, against about 9 in 100.7,13
  • Gallbladder. Gallstones affected about 16 in 1,000 people on Wegovy, against 7 in 1,000 on a dummy injection. An inflamed gallbladder affected about 6 in 1,000 on Zepbound, against 2 in 1,000.7,13
  • Pancreatitis (an inflamed pancreas): severe stomach pain that won’t go away, sometimes spreading to the back.7
  • Dehydration from vomiting or diarrhea can harm the kidneys.7
  • Thyroid and pregnancy. Not for anyone with a personal or family history of medullary thyroid cancer, or MEN 2. Canada’s obesity guideline advises against these medicines in pregnancy, while breastfeeding or when trying to conceive.13,6
Full detail in our side effects guide →
Get help now: call 911 or go to the nearest emergency department for severe stomach pain that won’t go away, with or without vomiting. It can be pancreatitis. Not sure? Call 811 to speak to a nurse in most provinces (Info-Santé 811 in Quebec).7,14

What about Quebec, and personal plans?

In Quebec everyone must have drug insurance, so private plans and RAMQ interact. Personal (non-group) plans are less likely to cover weight-loss drugs.15,16

Quebec is the only province where the whole population must be covered by a drug insurance plan.15 The benefits manager’s form notes that for Quebec members, “RAMQ exception drug criteria may apply”.3

Saskatchewan Blue Cross told members in 2024 that “Personal health plans will not cover Wegovy”, while some group plans would, with special authorization.16

Questions people ask

Is Ozempic covered by insurance in Canada?

For type 2 diabetes, usually: at least 88% of employers in a 2026 survey covered GLP‑1s for diabetes. Many plans now pay only the generic price.1,9

Is Wegovy covered by private insurance?

Sometimes. In 2026, 37% of Canadian employers covered GLP‑1s for weight loss, usually with a prior authorization form.1,3

What BMI do insurers ask for?

One benefits manager’s Wegovy form asks for a BMI of 30 or more, or 27 or more with a weight-related condition. Your own plan may differ.3

Who pays for the prior authorization form?

The form we read says fees for completing it are the plan member’s responsibility.3

What happens at renewal?

The form asks for a loss of 5% or more of body weight since the start, with dates and weights.3

How we researched this

We read the 2026 employer survey from the International Foundation of Employee Benefit Plans, Telus Health data as reported by Benefits and Pensions Monitor, Blue Cross bulletins, and one benefits manager’s published Wegovy prior authorization form.

Every plan sets its own rules. The form here is an example, not your plan’s criteria.

Before you move on

  • Find your plan’s drug list or call the number on your card.
  • Ask whether weight management is covered at all.
  • Ask for the prior authorization form before your appointment.
  • Ask your prescriber about any form fee.
  • Keep your starting weight on record for renewal.
Cost calculatorGetting a prescription, and the medicinesQuestions for your doctor

More from the Canada blog

CACanadaWhy doesn’t any province cover Wegovy or Zepbound for weight loss?CACanadaDoes your province cover Ozempic? Ontario, BC, Alberta, Quebec and others comparedCACanadaHow much do Ozempic, Wegovy, Mounjaro and Zepbound cost in Canada?
About GLP Guidebook

The monthly Canada update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: Health Canada approvals, recalls, provincial coverage changes and official prices. How we write

Was this post easy to understand?

Sources

  1. International Foundation of Employee Benefit Plans. GLP-1 drug trends: Canadian employers continue to increase coverage for weight loss (2026 pulse survey). 7 July 2026. Link
  2. Benefits and Pensions Monitor. Canadian GLP-1 weight-loss coverage more than doubles to 37% since 2024: study (diabetes-only coverage 51% in 2026, 66% in 2024). 13 July 2026. Link
  3. Express Scripts Canada. Prior Authorization Request: Wegovy (semaglutide) (initial criteria BMI 30 or more, or 27 or more with a weight-related condition; renewal at 5% weight loss; previously tried therapies; form fees paid by the plan member; off-label requests may be denied; RAMQ criteria may apply in Quebec). Checked 12 October 2026. PDF
  4. Benefits and Pensions Monitor. Can benefit plans stomach the $77 million weight-loss drug bill? (Telus Health data for 2024.) Link
  5. Health Canada. Drug Product Database: status records for every semaglutide product (Ozempic, Rybelsus, Wegovy, Plosbrio, Poviztra; generics from Dr. Reddy’s, Apotex, Aspen and Sandoz, and Sevmia). Searched 12 October 2026. Link
  6. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Canadian Adult Obesity Clinical Practice Guideline: Pharmacotherapy for Obesity Management in Adults, 2025 update. Obesity Canada, Version 3, 11 August 2025 (recommendations 1–13; six medicines approved for obesity; off-label use discouraged; pregnancy). PDF
  7. Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, date of authorization 2 October 2026 (indications; dose escalation; STEP 1–3 results and adverse reactions; pancreatitis, gallbladder, kidney and pregnancy warnings; storage). PDF
  8. Canada’s Drug Agency (CDA-AMC). Semaglutide (Wegovy) reimbursement recommendation SR0841, July 2025 (“Reimburse with conditions” for adults with BMI 27 or more and established cardiovascular disease; renewal at 5% loss; 67% price reduction; earlier 2022 recommendation against). Link
  9. Alberta Blue Cross. Pharmacy Benefact 1331, August 2026 (generic pricing for Ozempic claims under private plans that follow generic pricing, from 17 August 2026; LCA pricing suspended for government programs). PDF
  10. Saskatchewan Blue Cross. Generic Ozempic in Saskatchewan: what it means for your clients and members (generics added to the Saskatchewan Drug Plan Formulary 1 July 2026, interchangeable, Exception Drug Status; “They will not be considered for off label uses, including chronic weight management”). 7 August 2026. Link
  11. Novo Nordisk Canada. Ozempic (semaglutide injection) Product Monograph, 13 July 2026 (produced by recombinant DNA technology in yeast; 2, 4 and 8 mg pens; indications; adverse reactions table; pancreatitis; contraindications). PDF
  12. Eli Lilly Canada. Mounjaro (tirzepatide injection) Product Monograph, date of authorization 23 June 2026 (type 2 diabetes in adults and in ages 10 to under 18; single-dose pen, vial and 4-dose KwikPen; storage). PDF
  13. Eli Lilly Canada. Zepbound (tirzepatide injection) Product Monograph, date of authorization 11 June 2026 (indications; “The ZEPBOUND multi-dose KwikPen contains 4 doses”; doses; SURMOUNT-1 and -2 results and adverse reactions; coadministration with Mounjaro not recommended; contraindications). PDF
  14. Heart and Stroke Foundation of Canada. Medical services by phone (811 in most provinces and Yukon; Info-Santé 811 in Quebec; other numbers in Manitoba, the Northwest Territories and Nunavut). Checked 12 October 2026. Link
  15. Gouvernement du Québec. Régime public d’assurance médicaments: Quebec is “la seule province canadienne où toute la population est obligatoirement couverte par un régime d’assurance médicaments”. 29 December 2020. Link
  16. Saskatchewan Blue Cross. Coverage and new special authorization requirements for chronic weight management products (“Personal health plans will not cover Wegovy”; added with special authorization to some group plans from 1 June 2024). 22 May 2024. Link

Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your family doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write